The estimated Net Worth of Christopher Richard Anzalone is at least $131 Million dollars as of 31 January 2024. Christopher Anzalone owns over 57,499 units of Arrowhead Pharmaceuticals stock worth over $78,997,134 and over the last 16 years he sold ARWR stock worth over $50,265,057. In addition, he makes $2,216,260 as President, Chief Executive Officer, and Director at Arrowhead Pharmaceuticals.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Christopher Anzalone ARWR stock SEC Form 4 insiders trading
Christopher has made over 36 trades of the Arrowhead Pharmaceuticals stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 57,499 units of ARWR stock worth $836,035 on 31 January 2024.
The largest trade he's ever made was selling 300,000 units of Arrowhead Pharmaceuticals stock on 13 March 2018 worth over $2,229,000. On average, Christopher trades about 38,677 units every 80 days since 2008. As of 31 January 2024 he still owns at least 3,772,547 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Christopher Anzalone stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Anzalone biography
Dr. Christopher Richard Anzalone Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, from 1999 until 2003, he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring and building new business ventures. Dr. Anzalone holds a PhD. in Biology from UCLA and a B.A. in Government from Lawrence University.
What is the salary of Christopher Anzalone?
As the President, Chief Executive Officer, and Director of Arrowhead Pharmaceuticals, the total compensation of Christopher Anzalone at Arrowhead Pharmaceuticals is $2,216,260. There are no executives at Arrowhead Pharmaceuticals getting paid more.
How old is Christopher Anzalone?
Christopher Anzalone is 50, he's been the President, Chief Executive Officer, and Director of Arrowhead Pharmaceuticals since 2007. There are 15 older and 1 younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.
What's Christopher Anzalone's mailing address?
Christopher's mailing address filed with the SEC is 177 E. COLORADO BLVD, SUITE 700, PASADENA, CA, 91105.
Insiders trading at Arrowhead Pharmaceuticals
Over the last 20 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone, and Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.
What does Arrowhead Pharmaceuticals do?
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
What does Arrowhead Pharmaceuticals's logo look like?
Complete history of Christopher Anzalone stock trades at Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals executives and stock owners
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Christopher Anzalone,
President, Chief Executive Officer, Director -
Kenneth Myszkowski,
Chief Financial Officer -
Dr. Christopher R. Anzalone,
CEO, Pres & Director -
Patrick O'Brien,
General Counsel -
Kenneth A. Myszkowski,
Chief Financial Officer -
Dr. Javier San Martin M.D.,
Chief Medical Officer -
Dr. Javier San Martin,
Chief Medical Officer -
Douglass Given,
Chairman of the Board -
Michael Perry,
Lead Independent Director -
James Hassard,
Chief Commercial Officer -
Dr. Bruce D. Given,
Advisor -
William Waddill,
Independent Director -
Mauro Ferrari,
Independent Director -
Vincent Anzalone,
IR Contact Officer -
Oye Olukotun,
Independent Director -
Marianne De Backer,
Independent Director -
Javier San Martin,
Chief Medical Officer -
James Hassard,
Chief Commercial Officer -
Curt Bradshaw,
Chief Scientific Officer -
Dr. Mark Seefeld,
Head of Toxicology & VP -
Dr. James C. Hamilton,
Sr. VP of Discovery & Translational Medicine -
Patrick O'Brien,
Chief Compliance Officer, Gen. Counsel & Corp. Sec. -
Howard Lovy,
Director of Communications -
Jane Davidson,
Head of HR & Admin., VP and Corp. Sec. -
Dr. Mark M. Davis,
Founder and Founder & Director of Insert Therapeutics Inc & Calando -
Bruce D Given,
Chief Operating Officer -
Edward W Frykman,
Director -
David M Knott,
10% owner -
Douglas B Given,
Director -
David L. Lewis,
Chief Scientific Officer -
Joseph Theodore Iii Kingsley,
Chief Financial Officer -
Zhen Li,
Snr. VP, Chem and Non-Clin Dev -
Peter Brian Leone,
VP, Strategy & Program Mgmt -
Victoria Vakiener,
Director -
Leon Ekchian,
President -
Marshall Robert Ching,
10% owner -
James M Jr Phillips,
Secretary -
Charles Mc Kenney,
Director -
R Bruce Stewart,
President -
Leroy T Rahn,
Director -
Paul Clayton Mc Donnel,
Chief Financial Officer -
James C Hamilton,
Chief Discovery/Trans Medicine -
Hongbo Lu,
Director -
Tracie Oliver,
Chief Commercial Officer